Phase II Trial Using RAD001 for Patients with Radioiodine Refractory Thyroid Cancer

ID Number 11-0258

Principal Investigator(s)
Krzysztof J. Misiukiewicz

Department(s) or Division(s)
Hematology and Medical Oncology

Description

The purpose of this study is to collect information on the safety of RAD001 (Everolimus) and to learn how effective RAD001 is in treating your type of cancer. Information from other research studies suggest that RAD001 may help to decrease the growth and development of tumor cells by reducing the blood supply that tumors need to grow.

RAD001 is called investigational because it is not approved for use by the US Food and Drug Administration(FDA) in the treatment of Thyroid cancer. RAD001 is already approved for the treatment of renal cancer in the US.

You may qualify to take part in this research study because you have cancer of the thyroid.

Contact Information
(212) 824-7295
(212) 824-7293


Recruiting Patients: Yes